1 terminated, 1 unknown. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Terminated 1, Unknown 1 |
Follow GPI-0100: new trials by email Literature Review of GPI-0100 trials Research Report on GPI-0100
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy Study of TVGV-1 Vaccine to Treat HPV Induced Cervical HSIL TVGV-1, GPI-0100, Placebo - Human Papillomavirus, High-Grade Squamous Intraepithelial Lesions | Phase 2 | Unknown | THEVAX Genetics Vaccine | 10 | 2015-11-01 | 2017-10-25 |
| A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma EC90 (KLH-FITC), GPI-0100, EC17 (Folate-FITC) - Renal Cell Carcinoma | Phase 2 | Terminated | Endocyte | 12 | 2007-06-01 | 2012-03-08 |
Carcinoma, Renal Cell (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Squamous Intraepithelial Lesions (1) · Uterine Cervical Dysplasia (1)
Endocyte (1) · THEVAX Genetics Vaccine (1)
United States (2)
Frank L Douglas, PhD, MD (1) · Richard A Messmann, MD, MHS, BSc (1)